Johnson & Johnson (JNJ) Asset Writedowns and Impairment (2009 - 2026)

Johnson & Johnson has disclosed Asset Writedowns and Impairment across 18 years of filings, most recently posting $184.0 million for Q2 2026.

• In Q2 2026, Asset Writedowns and Impairment changed N/A year-over-year to $184.0 million; the TTM figure through Jun 2026 stood at $394.0 million (up 603.57% YoY), while the FY2025 annual figure was $204.0 million, down 49.63% from the prior year.
• Asset Writedowns and Impairment came in at $184.0 million for Q2 2026 at Johnson & Johnson, up from $36.0 million in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $610.0 million in Q2 2022 to a low of -$38.0 million in Q3 2023.
• Average Asset Writedowns and Impairment over 5 years is $213.3 million, with a median of $184.5 million recorded in 2024.
• Year-over-year, Asset Writedowns and Impairment surged 4257.14% in 2022 and tumbled 94.53% in 2024.
• Over 5 years, Asset Writedowns and Impairment stood at $610.0 million in 2022, then slipped by 22.13% to $475.0 million in 2023, then plunged by 94.53% to $26.0 million in 2024, then jumped by 211.54% to $81.0 million in 2025, then surged by 127.16% to $184.0 million in 2026.
• Per Business Quant data, the three most recent Asset Writedowns and Impairment figures were $184.0 million in Q2 2026, $36.0 million in Q1 2026, and $81.0 million in Q4 2025.